Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo and etanercept in pediatric severe chronic plaque psoriasis
MOH_2017-03-12_000126Phase 3Completed
- Sponsor
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoints: PASI 75 response at Week 12 and IGA mod 2011 0 or 1 response at Week 12. Status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2017-03-12_000126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-12_000126.